For drugs treating specialty and rare diseases, the average delta between forecasted peak sales and actual revenue is $405 million. Are you willing to take that sort of risk by relying on the typical product launch and commercialization playbook?

Enter IPM.ai

With a highly sophisticated system of insight utilizing ML/AI and RWD, we help uncover undiagnosed and misdiagnosed patients and identify their healthcare ecosystem, so patients can get critical life-improving treatments and commercial leaders can hit revenue forecasts.